05-Jan-2021 - Evotec SE

Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb

Evotec receive a US$ 6 m payment

Evotec SE announced that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio.

Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated the collaboration in 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.

This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s unique technology platforms in conjunction with the human iPSC-based platform, which is one of the largest and most sophisticated platforms in the industry. The partnership between Bristol Myers Squibb and Evotec has already found several access points into neurodegenerative diseases and has to-date delivered a broad portfolio targeting key disease mechanisms in neurodegeneration. 

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very excited about this most recent expansion of our joint project portfolio which further validates our iPSC-based approach within our strategic neuroscience partnership with Bristol Myers Squibb. Our partnership with Bristol Myers Squibb is driven by the firm belief that iPSC-based approaches will deliver more disease-relevant drug candidates which will have a better chance to deliver safe and effective drugs than traditional approaches.”

The milestone was achieved before the end of 2020.

Facts, background information, dossiers
  • Evotec
  • Bristol-Myers Squibb
  • neurodegenerative diseases
More about Evotec
  • News

    Evotec and Sartorius partner with start-up Curexsys on iPSC-based exosome approach

    Evotec SE Sartorius announced that they have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes. Curexsys delivers a proprietary isolation technology for exosomes ba ... more

    Evotec expands Oxfordshire site into a fully-integrated R&D centre

    Evotec SE announced the expansion of the Company’s existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 bi ... more

    Evotec and Novo Nordisk form alliance to develop novel therapies for kidney diseases

    Evotec SE and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease. Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets ... more

  • Companies

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

More about Bristol-Myers Squibb
  • News

    Evotec and Bristol-Myers Squibb expand iPSC collaboration

    Evotec SE announced that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines. Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 201 ... more

    Bristol-Myers Squibb Names Karen Vousden to Board of Directors

    Bristol-Myers Squibb Company announced that its Board of Directors has elected Karen Vousden, Ph.D., to the Board, effective January 1, 2018. Dr. Vousden will serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden, 60, is currently group leader at t ... more

    Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics

    Bristol-Myers Squibb Company announced that it has completed the previously announced planned acquisition of IFM Therapeutics. The transaction includes full rights to IFM’s preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune r ... more

  • Companies

    Bristol-Myers Squibb Co.

    The Bristol-Myers Squibb Research and Development (R&D) organization is one of the world's most innovative, productive, and respected scientific research organizations. Our purpose is: to discover and develop innovative, cost-effective medicines that address significant unmet medical needs ... more

    Bristol-Myers Squibb GmbH & Co. KGaA

    Our commitment is to research, develop and deliver innovative medicines that help patients overcome serious diseases. more

    Bristol-Myers Squibb GesmbH

    We promise our patients and customers, our employees and shareholders, the company and the environment, as well as all other contact persons, to remain convinced that each of our products reflects our integrity as a manufacturer. We pursue a sustainable and efficient management of the compa ... more